ExcepGen, a pioneering company in the genetic medicine sector, has unveiled its innovative approach to nucleic acid therapeutics after securing $4 million in a recent funding round. This latest funding brings the company’s total seed capital to $14 million. The company’s technology focuses on enhancing nucleic acid therapeutics by encoding a unique “shield” protein, which optimizes cellular responses to foreign DNA or RNA and minimizes negative cell signaling.
Key Highlights
- ExcepGen successfully raised $4 million in its latest funding round, bringing its total seed funding to $14 million.
- The funding round was led by RA Capital Management and saw participation from Gravity Fund, Apollo Projects (Sam Altman), and other top-tier investors.
- The company’s technology aims to enhance the efficacy and tolerability of nucleic acid therapeutics by encoding a unique “shield” protein.
Source: PR Newswire
Notable Quotes
- “We are excited to support the potential of ExcepGen’s novel platform to enhance nucleic acid therapeutics across a broad range of indications,” – Cosmas Giallourakis, Venture Partner at RA Capital Management
- “Our mission at ExcepGen is to unlock nucleic acid medicines. This funding validates our aim to make RNA and DNA-based drugs a cornerstone of therapeutics. We are excited to use this new funding to prove out the value of our technology in different therapeutic spaces.” – Thomas Folliard, CEO and co-founder at ExcepGen
SoH's Take
- ExcepGen’s unveiling with significant funding indicates the high potential and confidence investors have in the company’s nucleic acid therapeutics technology.
- The company’s unique “shield” protein approach could redefine the genetic medicine sector, potentially leading to more effective and tolerable DNA and RNA-based treatments.
